Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cellectar Biosciences ( (CLRB) ) has provided an update.
On October 7, 2025, Cellectar Biosciences entered into warrant exercise inducement offer letters with certain holders of existing warrants, leading to the exercise of these warrants for cash and the issuance of new inducement warrants. This transaction, which closed on October 8, 2025, generated approximately $5.8 million in gross proceeds, expected to fund the company’s operations into the third quarter of 2026.
The most recent analyst rating on (CLRB) stock is a Hold with a $12.40 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.
Spark’s Take on CLRB Stock
According to Spark, TipRanks’ AI Analyst, CLRB is a Underperform.
Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company’s valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.
To see Spark’s full report on CLRB stock, click here.
More about Cellectar Biosciences
Cellectar Biosciences, Inc. is a Delaware-based company operating in the biotechnology industry. The company focuses on developing innovative cancer treatments and therapies.
Average Trading Volume: 125,611
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.26M
For a thorough assessment of CLRB stock, go to TipRanks’ Stock Analysis page.